AXNX Company Profile and Key Details
NASDAQ : AXNX
Axonics
$70.98
N/A-
Open: 4:00 PMNot Actively Trading
67.73
BESG ScoreESG Rating
Price Chart
Stock Price Today
Axonics, Inc. (AXNX) stock remained unchanged at -, trading at $70.98 on NASDAQ, unchanged from the previous close of -. The stock opened at -, fluctuating between $70.98 and $70.98 in the recent session.
Stock Snapshot
N/A
Prev. Close
3.63B
Market Cap
70.98
Day Low
-709.8
P/E Ratio
-0.1
EPS (TTM)
-0.11
Cash Flow per Share
N/A
Open
51.11M
Number of Shares
70.98
Day High
98.71%
Free Float in %
12.91
Book Value
0
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
Annual Report (10-k)
Stock Price History Chart
Contact Details
About Company
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Company Information
| Employees | 797 |
| Beta | 0.83 |
| Sales or Revenue | $366.38M |
| 5Y Sales Change% | 72.885% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |
Stock Peers
BRKRP
10.33+2.95%
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$360.16SWAV-0.08-0.02%
ShockWave Medical, Inc.$334.75PODD-3.26-1.11%
Insulet Corporation$289.62UFPT4.54+2.02%
UFP Technologies, Inc.$229.40IRTC5.69+3.38%
iRhythm Technologies, Inc.$174.17ALGN-3.75-2.32%
Align Technology, Inc.$157.69TMDX6.6+5.45%
TransMedics Group, Inc.$127.67IRMD0.85+0.88%
IRadimed Corporation$97.19NARI00
Inari Medical, Inc.$79.97ESTA4.825+6.93%
Establishment Labs Holdings Inc.$74.42Company Overview
The stock is currently trading near its 52-week high $70.98 and $70.98. With a market capitalization of about $3.63 billion, Axonics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.83). Headquartered in Irvine, CA, Axonics, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Raymond W. Cohen, the company employs approximately 797 people and listed since October 31, 2018. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 0.86%, SMA50 1.65%, SMA200 3.84%). The stock’s 14-day RSI is 79.35 (overbought), while the ATR of 0.24 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -0.1% below its high and over 28.84% above its low.
Valuation Metrics
Axonics, Inc. trades at a P/E ratio of 527.22, slightly above the S&P 500 average, with a price-to-sales ratio of 15.72 and a price-to-book ratio of 5.46 trading at moderately above to book value. The P/FCF stands at 271.84, also above market averages.
Dividend & Fair Value
Axonics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.19. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Axonics, Inc. generated EPS of -$0.11 over the past year. Five-year average earnings growth is 36.15%. Wall Street analysts project EPS growth of 49.0% annually over the next five years. The latest quarter delivered EPS of $0.16. The next quarter is forecast at $0.24. Next year's EPS is expected at $347.79. Axonics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 07, 2024, missed forecasts by 23.08%. The prior quarter beat by 62.5%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in July 27, 2023.
Shareholding & Insider Activity
Axonics, Inc. has 51.11 million shares outstanding. The public float is 50.45 million shares, elevated short interest at 7.31% of float. This equals 3.31 million shares. The short ratio is 7.14 days. Institutional investors hold 88.34% of the float. Insiders own 1.26%. COHEN RAYMOND W holds 188.84 thousand shares, Woock John has 77.40 thousand shares and Ford Alfred J Jr has 43.45 thousand shares.
Financial & Profitability Overview
On valuation metrics, Axonics trades at a P/E of 527.22, P/S of 15.72 and P/B of 5.46. The current ratio is 8.16 and quick ratio is 6.40. Operationally, the company’s inventory turnover is 0.48 and cash conversion cycle is 730.31 days. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of 0.55.
Quarterly Financial Highlights
The company ended the quarter with $344.96M in cash and short-term investments, a total debt of $27.62M, and net debt of - $77.19M. Total assets were $719.92M, with equity of $637.56M. Financials further reflected weakness, with operating cash flow of - $2.02M, free cash flow of - $5.57M, and capital expenditures of - $3.55M.
Price Forecast & Outlook
Our AI price prediction model suggests that Axonics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.73%, with price expected at $71.50 by November 29, 2024, within a range of $70.93 to $72.08 3-Month Outlook: Projected rise of 15.02%, reaching $81.64 by February 13, 2025, with a range of $78.86 to $84.47. 1-Year Outlook: Projected gain of 4.2%, with price at $73.96 by November 14, 2025, within a range of $71.61 to $76.79.
Key Takeaways
Axonics, Inc. (NASDAQ:AXNX) shares are up 14.06% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Axonics, Inc. trading at a premium to the broader market with a P/E of 527.22. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $66.72, suggesting -6.0% downside. Our AI forecast model points to short-term strength (0.73% over two weeks), a medium-term rise (15.02% over three months), and a longer-term gain (4.2% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Axonics, Inc. (AXNX) stock price?
Axonics, Inc. (NASDAQ: AXNX) stock price is $70.98 in the last trading session. During the trading session, AXNX stock reached the peak price of $70.98 while $70.98 was the lowest point it dropped to. The percentage change in AXNX stock occurred in the recent session was N/A while the dollar amount for the price change in AXNX stock was -.
AXNX's industry and sector of operation?
The NASDAQ listed AXNX is part of Medical - Devices industry that operates in the broader Healthcare sector. Axonics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of AXNX?
Dr. Karen L. Noblett M.A.S., M.D.
Chief Medical Officer
Mr. Danny L. Dearen
Pres & Chief Financial Officer
Mr. Alfred J. Ford Jr.
Chief Commercial Officer
Mr. Guangqiang Jiang Ph.D.
Chief Technology Officer
Mr. Neil Bhalodkar
Vice President of Investor Relations
Mr. Raymond W. Cohen
Chief Executive Officer & Director
Mr. Rinda K. Sama
Chief Operating Officer
Mr. Michael V. Williamson Esq., J.D.
Senior Vice President, Gen. & IP Counsel
Mr. Aaron Pettit
Gen. Counsel & Chief Compliance Officer
Dr. John Woock Ph.D.
Executive Vice President, Chief Marketing & Strategy Officer
Chief Medical Officer
Mr. Danny L. Dearen
Pres & Chief Financial Officer
Mr. Alfred J. Ford Jr.
Chief Commercial Officer
Mr. Guangqiang Jiang Ph.D.
Chief Technology Officer
Mr. Neil Bhalodkar
Vice President of Investor Relations
Mr. Raymond W. Cohen
Chief Executive Officer & Director
Mr. Rinda K. Sama
Chief Operating Officer
Mr. Michael V. Williamson Esq., J.D.
Senior Vice President, Gen. & IP Counsel
Mr. Aaron Pettit
Gen. Counsel & Chief Compliance Officer
Dr. John Woock Ph.D.
Executive Vice President, Chief Marketing & Strategy Officer
How AXNX did perform over past 52-week?
AXNX's closing price is 0% higher than its 52-week low of $70.98 where as its distance from 52-week high of $70.98 is 0%.
How many employees does AXNX have?
Number of AXNX employees currently stands at 797.
Link for AXNX official website?
Official Website of AXNX is: https://www.axonics.com
How do I contact AXNX?
AXNX could be contacted at phone 949 396 6322 and can also be accessed through its website. AXNX operates from 26 Technology Drive, Irvine, CA 92618, United States.
How many shares of AXNX are traded daily?
AXNX stock volume for the day was 0 shares. The average number of AXNX shares traded daily for last 3 months was 0.
What is the market cap of AXNX currently?
The market value of AXNX currently stands at $3.63B with its latest stock price at $70.98 and 51.11M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep